Acute respiratory distress syndrome (ARDS) is a syndrome of acute respiratory failure
caused by noncardiogenic pulmonary edema. Despite five decades of basic and clinical …

Mesenchymal stem (stromal) cells (MSCs) are multipotent cells with the ability to differentiate
into several cell types, thus serving as a cell reservoir for regenerative medicine. Much of the …

Background Treatment with bone-marrow-derived mesenchymal stromal cells (MSCs) has
shown benefits in preclinical models of acute respiratory distress syndrome (ARDS). Safety …

Background Acute respiratory distress syndrome (ARDS) is a fatal complication of
coronavirus disease 2019 (COVID-19). There are a few reports of allogeneic human …

Mesenchymal stem cells (MSCs) and macrophages are fundamental components of the
stem cell niche and function coordinately to regulate haematopoietic stem cell self-renewal …

The clinical description that defines acute lung injury (ALI) has been around for more than
50 years. The clinical picture has carried many different definitions, but what was known as …

Background No effective pharmacotherapy for acute respiratory distress syndrome (ARDS)
exists, and mortality remains high. Preclinical studies support the efficacy of mesenchymal …

The acute respiratory distress syndrome (ARDS) is an important cause of acute respiratory
failure that is often associated with multiple organ failure. Several clinical disorders can …

Mesenchymal stem cells (MSCs), the major stem cells for cell therapy, have been used in
the clinic for approximately 10 years. From animal models to clinical trials, MSCs have …

Mesenchymal stem cells (MSCs), whose mechanism of action is predominantly paracrine,
are being widely tested for the treatment of a variety of human diseases. No one factor has …